Russell Investments Group Ltd. increased its stake in shares of Enhabit, Inc. (NYSE:EHAB – Get Rating) by 84.2% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 227,706 shares of the company’s stock after purchasing an additional 104,117 shares during the quarter. Russell Investments Group Ltd. owned approximately 0.46% of Enhabit worth $2,997,000 at the end of the most recent reporting period.
Other institutional investors have also added to or reduced their stakes in the company. Northern Trust Corp acquired a new position in Enhabit in the 2nd quarter valued at approximately $494,000. Millennium Management LLC acquired a new position in Enhabit in the 2nd quarter valued at approximately $230,000. Raymond James Financial Services Advisors Inc. acquired a new position in Enhabit in the 3rd quarter valued at approximately $585,000. Raymond James & Associates bought a new stake in shares of Enhabit in the 3rd quarter valued at $795,000. Finally, Comerica Bank bought a new stake in shares of Enhabit in the 3rd quarter valued at $1,690,000. 95.55% of the stock is currently owned by institutional investors and hedge funds.
Enhabit Stock Performance
EHAB opened at $11.89 on Friday. The company has a current ratio of 1.57, a quick ratio of 1.59 and a debt-to-equity ratio of 0.71. The company’s fifty day moving average price is $13.05 and its two-hundred day moving average price is $13.65. Enhabit, Inc. has a 1-year low of $11.50 and a 1-year high of $25.25. The company has a market cap of $595.69 million and a price-to-earnings ratio of 15.24.
Wall Street Analysts Forecast Growth
EHAB has been the topic of a number of analyst reports. Citigroup reduced their price objective on shares of Enhabit from $18.00 to $15.00 in a research note on Friday, May 12th. Stifel Nicolaus upped their price objective on shares of Enhabit from $17.00 to $18.00 in a research note on Wednesday, February 15th. Credit Suisse Group reaffirmed a “neutral” rating and issued a $15.00 price objective on shares of Enhabit in a research note on Thursday, February 16th. Finally, The Goldman Sachs Group started coverage on shares of Enhabit in a research note on Thursday, March 16th. They set a “neutral” rating and a $15.00 target price on the stock. Two analysts have rated the stock with a sell rating, five have given a hold rating and two have given a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $16.13.
Enhabit, Inc provides home health and hospice services in the United States. Its home health services include patient education, pain management, wound care and dressing changes, cardiac rehabilitation, infusion therapy, pharmaceutical administration, and skilled observation and assessment services; practices to treat chronic diseases and conditions, including diabetes, hypertension, arthritis, Alzheimer's disease, low vision, spinal stenosis, Parkinson's disease, osteoporosis, complex wound care and chronic pain, along with disease-specific plans for patients with diabetes, congestive heart failure, post-orthopedic surgery, or injury and respiratory diseases; and physical, occupational and speech therapists provide therapy services.
- Get a free copy of the StockNews.com research report on Enhabit (EHAB)
- Applied Materials: Cracks In The Chip Recovery Or Time To Buy?
- Deere & Company Rallies On Farm Equipment Boom, Bullish Outlook
- How Many Roth IRAs Can You Have?
- Why You Should Consider Buying Nvidia Ahead Of Earnings
- Foot Locker And The Ebbing Tide Of Discretionary Spending
Receive News & Ratings for Enhabit Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enhabit and related companies with MarketBeat.com's FREE daily email newsletter.